Hasegawa Sho, Kobayashi Noritoshi, Tokuhisa Motohiko, Goto Ayumu, Takano Shoko, Takada Yuuki, Kaneta Tomohiro, Mori Ryutaro, Matsuyama Ryusei, Endo Itaru, Yamanaka Shoji, Nakajima Atsushi, Inoue Tomio, Ichikawa Yasushi
Oncology Division, Yokohama City University Hospital, Yokohama, Japan.
Digestion. 2017;96(1):13-20. doi: 10.1159/000470838. Epub 2017 Jun 14.
BACKGROUND/AIMS: Somatostatin receptor (SSTR) scintigraphy (SRS) is the standard imaging modality for evaluation of gastroenteropancreatic neuroendocrine tumor (GEP-NET) in Western countries. However, this modality was not approved in Japan until recently. The purpose of this study was to evaluate the clinical efficacy of SRS for detecting GEP-NET in Japanese patients.
Japanese patients with advanced GEP-NET were enrolled and evaluated by the SRS and CT. We also compared SRS and immunohistochemical expression of SSTR type 2a (SSTR2a).
We enrolled 16 patients and the primary sites were the pancreas in 9, the stomach in 1, the small intestine in 2, the colon in 3, and unknown in 1. SRS showed positive findings in 3 (100%) of grade 1 (G1) and in 12 (92.3%) of grade 2 (G2) lesions. In the liver, SRS and CT detected lesions in 13 and 14 cases, respectively. The concordance rate of SSTR2a expression with SRS findings was 93.8% in the whole body and 92.9% in the liver.
SRS could detect almost all of G1 and G2. SRS could be useful to detect lesions, with a high concordance rate with CT and pathological findings. We confirmed that SRS is a useful and reliable modality for Japanese patients.
背景/目的：在西方国家，生长抑素受体（SSTR）闪烁扫描术（SRS）是评估胃肠胰神经内分泌肿瘤（GEP-NET）的标准成像方式。然而，直到最近这种方式在日本才被批准。本研究的目的是评估SRS在检测日本患者GEP-NET中的临床疗效。
纳入日本晚期GEP-NET患者，并通过SRS和CT进行评估。我们还比较了SRS与2a型生长抑素受体（SSTR2a）的免疫组化表达。
我们纳入了16例患者，原发部位为胰腺的有9例，胃1例，小肠2例，结肠3例，1例原发部位不明。SRS在1级（G1）病变中有3例（100%）显示阳性结果，在2级（G2）病变中有12例（92.3%）显示阳性结果。在肝脏中，SRS和CT分别检测到13例和14例病变。SSTR2a表达与SRS结果的全身符合率为93.8%，肝脏符合率为92.9%。
SRS能检测出几乎所有的G1和G2病变。SRS对检测病变可能有用，与CT及病理结果的符合率较高。我们证实SRS对日本患者是一种有用且可靠的方式。
